1.Effects of Ar plasma treatment on water sorption and solubility of auto-polymerized acrylic resin
Huaiqin ZHANG ; Chunmei JIANG ; Jianglin FANG
Chinese Journal of Tissue Engineering Research 2008;12(45):8977-8979
A total of 62 disk-shaped specimens in the size of 30 mm (diameter) ×2 mm (layer thickness) were made with auto-polymerized acrylic resin (2 specimens for infrared spectrum comparison and 60 specimens for tests of water sorption and solubility). Duration of Ar plasma application was 2 minutes and plasma power applied was 60 W. Storage intervals were 1 day, 1 week, 1 month, 6 months, and 12 months, separately. A control group and a corresponding experimental group were set for each storage interval, with 6 specimens per group. All specimens were weighted 3 times, i.e., initial weight; weigh after absorption of distilled water, and final weight after desiccation. Percentages of water absorption and solubility of auto-polymefized acrylic resin were calculated. Results revealed that after Ar plasma treatment, C-H structure of auto-polymerized acrylic resin was reduced; following 1-month storage interval, water absorption percentage was significantly lower in the experimental group than in the control group; following 1-day, 1-week, and 1-month storage interval, the experimental group exhibited significantly lower solubility of auto-polymerized acrylic resin, compared to the control group (P<0.05). These results indicated that within 1-month storage, Ar plasma treatment can decrease water sorption and solubility of auto-polymerized acrylic resin.
2.Drugs administration and individual affordability under different medical insurance entry price:Example of Anti-tumor Targeted Medicare Drugs
Xin FANG ; Mengyuan TIAN ; Yuxiao ZHANG ; Xiao YIN ; Jianglin HU ; Dan CUI
Chinese Journal of Health Policy 2016;9(11):40-44
Objective: To analyze the New Cooperative Medical System ( NCMS ) funds and Individual afford-ability of anti-tumor targeted drugs under different medical insurance entry price, and to provide the basis for establis-hing the access price for medical insurance. Methods: Choosing Conmana or Kemer ( the lung cancer targeted drug) and Herceptin (breast cancer targeted drug) to analyze the Wuhan NRCMS operating status from 2012 to 2014, use tumor surveillance data from Hubei Province during the period from 2011 to 2015;consult clinical experts to form expert consensus price, refer to the Jiangsu Province Access Price and National Negotiation Price, and explore the fund bal-ance and individual affordability when the afore-mentioned two kinds of drugs can be compensated by medical insurance under different price. Results:The basic account balances of NRCMS in Wuhan from 2016 to 2018 are-11. 948 million Yuan, 2. 513 million Yuan and 82. 955 million Yuan when Kemer can be compensated by medical insurance under Na-tional Negotiation Price. Taking the compensation of Herceptin under National Price after the bargaining, the basic ac-count balances are -26. 901 million Yuan,-35. 962 million Yuan and 17. 542 million Yuan respectively. The rate of poverty caused by illness falls to 33. 40% from 45. 85% when Conmana can be compensated by Medical Insurance un-der National Negotiation Price, while this rate falls to 45. 42% from 46. 00% for Herceptin. Conclusion:The two kinds of drugs can be afforded by the Wuhan NRCMS after the medical insurance access price is negotiated by the govern-ment, but the individual affordability of Herceptin at the National Negotiation Price is worse.
3.Affordability Evaluation for 3 Kinds of Anti-tumor Targeted Drugs:Taking Hubei Province as an Example
Mengyuan TIAN ; Dan CUI ; Yuxiao ZHANG ; Xiao YIN ; Xin FANG ; Jianglin HU
China Pharmacy 2017;28(20):2746-2749
OBJECTIVE:To evaluate the affordability of 3 anti-tumor targeted drugs gefitinib,trastuzumab and sunitinib in ur-ban and rural residents of Hubei province,and to provide reference for medical insurance price admission of anti-malignant tumor targeted drugs in China. METHODS:Referring to the incidence of malignant tumor stated in statistical yearbook of Hubei province and income data of urban and rural residents in Hubei province,based on the policy of reducing the price of imported drugs by 50% mentioned in the national drug price negotiations,and assume the drugs are included in the medical insurance reimbursement list,WHO/HAI standard survey method,catastrophic expenditure evaluation method and poverty effect evaluation method were ad-opted to calculate the affordability of 3 drugs. RESULTS:According to WHO/HAI standard survey method,increment of payment for 3 drugs were 64.00%-74.00% before and after 50% discount and reimbursement. According to catastrophic expenditure evalua-tion method,50% discount of gefitinib and reimbursement gefitinib,trastuzumab and sunitinib in urban area would result in cata-strophic expenditures of 20.00%、59.28% and 35.48% patients;in rural area,would result in catastrophic expenditures of 50.63%、74.72% and 75.93% patients. According to poverty effect evaluation method,50% discount of 3 drugs and reimbursement caused less than 31.95% urban and rural patients falling to poverty. CONCLUSIONS:Fifty percentage discount of 3 anti-tumor targeted drugs mentioned in the national drug price negotiations cause the economic burden more serious for rural residents than urban resi-dents. In the formulation of policies,the corresponding reimbursement ratio should be adjusted according to urban and rural areas, drug price and disease types for a balance of patients with different economic burden.
4.Smad pathway participates the process of proliferation of vascular smooth muscle cells induced by extracellular signal regulated kinase pathway
Da MU ; Fang HE ; Jianglin REN ; Huimin ZHANG ; Hua ZHONG ; Fengmei DENG ; Zhiping SUN
Chinese Journal of Pathophysiology 1986;0(04):-
AIM:To investigate whether Smad pathway participates the process of extracellular signal regulated kinase (ERK) induced the proliferation of vascular smooth muscle cells (VSMCs). METHODS: Human umbilical artery smooth muscle cells (hUASMCs) were divided into four groups: control group, PDGF (platelet derived growth factor) group, ERK blocking agent group and PDGF+ERK blocking agent group. MTT assay was used to detect the proliferation of hUASMCs (A value). Immunohistochemical technique was used to detect the expression of PCNA, phosphorylated ERK (p-ERK) and phosphorylated Smad2/3 (p-Smad2/3) protein in hUASMCs. The expression of Smad2/3 mRNA in hUASMCs was detected by RT-PCR. RESULTS: The proliferation of hUASMCs and the expression of PCNA, p-ERK and p-Smad2/3 proteins in hUASMCs in PDGF group were increased obviously than those in other groups (P
5.A multicenter, randomized, double-blind, controlled study on the injection of two kinds of dexamethasone palmitate in the treatment of rheumatoid arthritis
Junhua GUO ; Feng HUANG ; Jianglin ZHANG ; Husheng WU ; Hui SONG ; Huji XU ; Yu LIU ; Jieruo GU ; Jianlin HUANG ; Yongfei FANG ; Ronghua ZHANG
Chinese Journal of Rheumatology 2012;16(6):393-397
Objective To evaluate the efficacy and safety of two forms of preparations of dexamethasone palmitate in the treatment of rheumatoid arthritis (RA).Methods A multicenter,double-blind,randomized,parallel-group clinical trial was carried out according to good clinical practice (GCP).A total of 237cases of RA patients with mild to moderate knee swelling were randomly divided into the treatment group (n=118 ) or the control group (n=119) and were treated with two kinds of dexamethasone palmitate 8 mg injection respectively.The primary efficacy endpoints were the circumference of the knee joint at the upper and the lower edge after the intra-articular injection.The secondary efficacy endpoints were joint tenderness index and patients general assessment.The adveme events were recorded.Analysis of covariance,t test or Wilcoxon test,x2 test or Fisher exact test were used for statistical analysis.Results The upper edges of the treatment group and the control group after treatment were (37.2±3.3) cm and (36.4±3.9) cm respectively,and the lower edges of the two groups were (34.4±2.9) cm and (33.9±3.4) cm respectively.They were all significantly smaller than the edges before treatment [(38.1± 3.3) cm and (37.3±4.0) cm of the upper edges,(35.1±3.0)cm and (34.6±3.6) cm of the lower edges respectively ) (P<0.O1)].After treatment,the joint tenderness index were improved (P<0.01).A total ratio of great improvement and improvement of patients general assessment of the two group patients were 67.5% (79/117) and 74.8% (86/115) respectively.No statistical significant difference was found in all primary and secondary efficacy endpoints between the two groups (P>0.05).During the clinical trial,the incidence of adverse events related to the treatment of two groups were 4.2% and 6.8%,without any significant difference (P>0.05).Conclusion New preparation of dexamethasone palmitate has the same efficacy and safety as the imported producted in the treatment of RA.The circumference of the knee joints at the upper and the lower edge may be used to assess the effects of intra-articular injections.